Abstracts tagged "rheumatoid arthritis (RA) and tocilizumab"

Abstract Number: 2479 • 2014 ACR/ARHP Annual Meeting
Utility of Adjustment of Administration Interval in Tocilizumab in Rheumatoid Arthritis
Shuntaro Saito, Keisuke Izumi, Yuko Kaneko, Katsuya Suzuki and Tsutomu Takeuchi, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose Interleukin-6 (IL-6) is considered a key cytokine in the pathogenesis of rheumatoid arthritis (RA). Tocilizumab (TCZ) is a monoclonal antibody which binds to membrane-bound…
Abstract Number: 2133 • 2014 ACR/ARHP Annual Meeting
Efficacy of Tocilizumab Therapy in Patients with Rheumatoid Arthritis Based on FDG-PET/CT
Koichi Okamura¹, Yukio Yonemoto¹, Chisa Okura² and Kenji Takagishi¹, ¹Orthopaedic Surgery, Gunma University, Maebashi, Japan, ²Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan
Background/Purpose: A humanized anti-interleukin-6 receptor (anti-IL-6R) antibody, tocilizumab (TCZ), is one of the biologics and the C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR)…
Abstract Number: 2368 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Efficiently Halts Radiographic Progression In Patients With Rheumatoid Arthritis and Swollen Joint Counts Within a Year Predict Long-Term Radiographic Outcomes: Three Year Results From Michinoku Tocilizumab Study Group
Ryu Watanabe¹, Hiroshi Okuno², Tomonori Ishii¹, Yasuhiko Hirabayashi³ and Hideo Harigae¹, ¹Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ²Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan, ³Rheumatology, Hikarigaoka Spellman Hospital, Sendai, Japan
Background/Purpose: One of the important therapeutic goals in patients with rheumatoid arthritis (RA) is to halt radiographic progression. Tocilizumab (TCZ), an IL-6 receptor antibody, has…
Abstract Number: 2343 • 2013 ACR/ARHP Annual Meeting
Assessment Of Subclinical Atherosclerosis (Flow Mediated Dilatation and arterial stiffness) After 24 Weeks Of a Tocilizumab Therapy In 22 Patients With Rheumatoid Arthritis
Martin Soubrier¹, Thomas Frayssac², Bruno Pereira³, Marion Couderc Sr.⁴, Coline Daron², Jean Jacques Dubost⁵, Sandrine Malochet-Guinamand⁴, Anne Tournadre⁴ and Sylvain Mathieu⁴, ¹Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, ²CHU CLERMONT-FERRAND, Clermont-ferrand, France, ³Clinical research department, Clermont-Ferrand, France, ⁴Rheumatology CHU Gabriel Montpied, Clermont-Ferrand, France, ⁵Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France
Background/Purpose: Increased incidence of cardiovascular diseases and sub-clinical atherosclerosis have been observed in rheumatoid arthritis (RA). Inflammation and traditional risk factors could be involved in…
Abstract Number: 2327 • 2013 ACR/ARHP Annual Meeting
Dose Reduction Of Tocilizumab In Rheumatoid Arthritis Patients With Low Disease Activity Is Feasible
Noortje van Herwaarden¹, Susan Herfkens-Hol¹, Aatke van der Maas¹, Bart J.F. van Den Bemt², Ronald F. van Vollenhoven³, Johannes W.J. Bijlsma⁴ and Alfons A. den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands, ³Karolinska Institute, Stockholm, Sweden, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Tocilizumab, at a registered dose of 8mg/kg, has proven to be effective in the treatment of rheumatoid arthritis. Clinical trial data show that a…
Abstract Number: 2263 • 2013 ACR/ARHP Annual Meeting
ADAMTS5 Is a Biomarker For The Efficacy Prediction Of Tocilizumab In Rheumatoid Arthritis
Kensei Tsuzaka, Masako Takao and Jiro Nishida, Dept of Internal Medicine, Ichikawa General Hospital,TDC, Ichikawa, Chiba, Japan
a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) mRNA level. In this study presented here, we investigated whether the efficacy of tocilizumab (TCZ) for…
Abstract Number: 1479 • 2013 ACR/ARHP Annual Meeting
Relationship Between physicians’ Decision To Use Concomitant Glucocorticoid and Remission During Treatment With Tocilizumab In Patients With Background Of Limited Dose Of MTX
Toshihisa Kojima¹, Nobunori Takahashi², Koji Funahashi³, Shuji Asai¹, Masahiro Hanabayashi¹, Shinya Hirabara⁴, Nobuyuki Asai⁵ and Naoki Ishiguro², ¹Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ²Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ⁵Nagoya Univeristy Hospital, Nagoya, Japan
Background/Purpose: Now, predictive factors at baseline for the good outcome of treatment with biologics are very important not to waste time to treatment goal “remission”.…
Abstract Number: 1437 • 2013 ACR/ARHP Annual Meeting
Clinical and Radiographic Outcomes At Two Years and The Effect Of Tocilizumab Discontinuation Following Sustained Remission In The Second Year Of The ACT-RAY Study
Thomas W.J. Huizinga¹, Philip G. Conaghan², Emilio Martin-Mola³, Georg Schett⁴, Howard Amital⁵, Ricardo M. Xavier⁶, Orrin Troum⁷, Maher Aassi⁸, Corrado Bernasconi⁹ and Maxime Dougados¹⁰, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ⁴Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵The Zabludowicz Center For Autoimmune Diseases, and Department of Medicine 'B',, Sheba Medical Center,Tel-Hashomer, Tel-Aviv University, Tel-hashomer, Israel, ⁶Rheumatology Division, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul - Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ⁷University of Southern California School of Medicine, Santa Monica, CA, ⁸F. Hoffmann-La Roche, Basel, Switzerland, ⁹Consultant, Basel, Switzerland, ¹⁰Cochin Hospital, Paris, France
Background/Purpose: 24- and 52- week data from ACT-RAY comparing an add-on strategy (tocilizumab [TCZ] + methotrexate [MTX]) with a switch strategy (TCZ + placebo [PBO])…
Abstract Number: 1440 • 2013 ACR/ARHP Annual Meeting
Effects Of Tocilizumab On Serum Cytokines In Rheumatoid Arthritis With An Inadequate Response To Disease-Modifying Antirheumatic Drugs
Sang Jin Lee^1,2, Kyung Rok Kim³, Sang Hyun Joo³, Jae Myung Lee³, In Ah Choi³, Joo Youn Lee², Hyun Jung Yoo², Eun Young Lee⁴, Eun Bong Lee¹, Won Park⁵, Sung Hwan Park⁶, Seung-Cheol Shim⁷, Dae-Hyun Yoo⁸, Han Joo Baek⁹, Hyun Ah Kim¹⁰, Soo Kon Lee¹¹, Yun Jong Lee¹, Young Eun Park¹², Hoon-Suk Cha¹³ and Yeong Wook Song^2,3, ¹Division of Rheumatology, Department of Internal Medicine, Rheumatology, Seoul National University, Seoul, South Korea, ²Department of molecular medicine and biophamaceutical sciences,Seoul National University, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ⁴Internal medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Rheumatology, The Catholic University, Seoul, South Korea, ⁷Medicine, Rheumatology, Eulji University, Daejeon, South Korea, ⁸Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁹Rheumatology, Rheumatology, Gachon University, Incheon, South Korea, ¹⁰Division of Rheumatology, Department of Internal Medicine, Hallym university, Kyunggi, South Korea, ¹¹Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ¹²Rheumatology, Rheumatology, Pusan Nationl University, Pusan, South Korea, ¹³Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: The objective of this study was to investigate the effects of tocilizumab on serum cytokines in rheumatoid arthritis (RA) patients with an inadequate response…
Abstract Number: 1344 • 2013 ACR/ARHP Annual Meeting
Optimal Rheumatoid Arthritis Patient Selection For Biological Treatment From Pharmacoeconomic Perspectives Based On The Institute Of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort
Eiichi Tanaka¹, Eisuke Inoue², Yoko Shimizu³, Akiko Kobayashi², Naoki Sugimoto², Daisuke Hoshi², Kumi Shidara², Eri Sato³, Yohei Seto², Ayako Nakajima⁴, Shigeki Momohara², Atsuo Taniguchi² and Hisashi Yamanaka³, ¹Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: With the recent introduction of biological DMARDs, the economic burden of rheumatoid arthritis (RA) treatment has increased. Previous studies evaluated the cost-effectiveness of biologics,…
Abstract Number: 448 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of Tocilizumab In Monotherapy and In Combination With Different Synthetic Dmards: A Registry-Based Comparison Study
Cem Gabay¹, Myriam Riek², Merete Lund Hetland³, Ulrik Tarp⁴, K. Pavelka⁵, Matija Tomsic⁶, Helena Canhao⁷, Katerina Chatzidionysiou⁸, R.F. van Vollenhoven⁹, Galina Lukina¹⁰, E. Nasonov¹¹, Dan C. Nordström¹², Elisabeth Lie¹³, Ioan Ancuta¹⁴, Estibaliz Loza Santamaria¹⁵, Piet Van Riel¹⁶ and Tore K. Kvien¹³, ¹Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ²SCQM Registry, Zurich, Switzerland, ³DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁵Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁶Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia, ⁷Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Instituto de Medicina Molecular, Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Lisbon, Portugal, ⁸Dept of Medicine, Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden, ⁹Karolinska Institute, Stockholm, Sweden, ¹⁰ARBITER, Institute of Rheumatology, Moscow, Russia, ¹¹Institute of Rheumatology, Moscow, Russia, ¹²ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, ¹³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁴“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ¹⁵Instituto de salud Musculoesqueletica, Madrid, Spain, ¹⁶Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Tocilizumab (TCZ) is efficacious in monotherapy and in combination with methotrexate (MTX) or other DMARDs. However, longitudinal data from large registry populations are missing.…
Abstract Number: 451 • 2013 ACR/ARHP Annual Meeting
Evaluation Of Disease Activity By The Routine Assessment Of Patient Index Data 3 In Patients With Rheumatoid Arthritis Receiving Tocilizumab
Yu F. Asanuma¹, Takashi Maruyama², Maiko Yanagisawa², Kazuhiro Yokota³, Yoshihiro Yoshida², Hiroshi Kajiyama¹, Kojiro Sato¹, Yuji Akiyama¹ and Toshihide Mimura⁴, ¹Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, ²Saitama Medical University, Saitama, Japan, ³Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ⁴Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Interleukin-6 (IL-6) has been demonstrated to play a pathological role in rheumatoid arthritis (RA). IL-6 strongly induces production of C-reactive protein (CRP) and fibrinogen…
Abstract Number: 359 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Treatment Increases Left Ventricular Ejection Fraction and Decreases Left Ventricular Mass Index In Rheumatoid Arthritis Patients Without Cardiac Symptoms : Assessment By Cardiac Magnetic Resonance Imaging At 3.0 Tesla
Hitomi Kobayashi^1,2, Isamu Yokoe³, Hiroshi Sato², Yasuyuki Kobayashi⁴, Kihei Yoneyama⁵, Masaharu Hirano⁶ and Masami Takei⁷, ¹Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Rheumatology, Itabashi Chuo Medical Center, Tokyo, Japan, ³Nihon University School of Medicine, Tokyo, Japan, ⁴Radiology, St.Marianna University School of Medicine, Kawasaki, Japan, ⁵Cardiology, St.Marianna University School of Medicine, Kawasaki, Japan, ⁶Cardiology, Tokyo Medical Colleage, Tokyo, Japan, ⁷Division of Hematology and Rheumatology, NIhon University School of Medicine, Tokyo, Japan
Background/Purpose: Left ventricular (LV) dysfunction in rheumatoid arthritis (RA) may result, at least in part, from inflammation that may be regional and global. Therefore, therapies…
Abstract Number: 2827 • 2013 ACR/ARHP Annual Meeting
Effect Of Biologic Agents On Lipids and Cardiovascular Risk In Rheumatoid Arthritis Patients
Dimitrios A. Pappas¹, Ani John², Jeffrey R. Curtis³, George W. Reed⁴, Jeffrey D. Greenberg⁵, Ashwini Shewade², Daniel H. Solomon⁶, Joel M. Kremer⁷ and Tanya Sommers⁴, ¹Columbia University, New York, NY, ²Genentech Inc., South San Francisco, CA, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴CORRONA, Inc., Southborough, MA, ⁵Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY, ⁶Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁷Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: The risk for cardiovascular disease (CVD) is increased in patients (pts) with RA. The interplay between traditional CV risk factors and inflammatory burden may…
Abstract Number: 2387 • 2013 ACR/ARHP Annual Meeting
Change of serum Amyloid a predict The Effect Of Biological Treatment In Rheumatoid Arthritis Patient
Chisa Okura¹, Yukio Yonemoto², Koichi Okamura¹, Tetsuya Kaneko³, Tsutomu Kobayashi¹ and Kenji Takagishi¹, ¹Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, ²Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan, ³Department of Orthopaedic Surgery, Inoue Hospital, Takasaki, Gunma, Japan
Background/Purpose: The C-reactive protein (CRP) level and the erythrocyte sedimentation rate (ESR) are common markers of inflammation in patients with rheumatoid arthritis (RA). The serum…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].